Purpose: We aimed to compare imaging with ¹²³I-MIBG and ⁶⁸Ga-DOTA-TATE in neural crest tumours (NCT) to see if the latter could offer more advantage in detecting extra lesions and have higher sensitivity for malignant lesions. Procedures: We retrospectively reviewed 12 patients (M=10, F=2; age range 20-71 years) with NCT (phaeochromocytomas = 7, paragangliomas = 4, medullary thyroid cancer = 1) who underwent both ⁶⁸Ga-DOTA-TATE positron emission tomography (PET) or PET/computed tomography (CT) and ¹²³IMIBG single-photon emission computed tomography within 6months. Visual assessment of all lesions and measurement of target/non-target (T/N) ratio in selected lesions were performed. Five patients (aged 50 or less) had SDHB screening results correlated with imaging results of both radiopharmaceuticals. All patients had contrast-enhanced CT and/or other cross-sectional imaging. Results: ⁶⁸Ga-DOTA-TATE PET showed tumour lesions in ten out of 12 patients with confirmed disease, while ¹²³I-MIBG showed lesions in five out of 12 patients. In one patient, both ⁶⁸Ga-DOTATATE PET and ¹²³I-MIBG were negative, but CT, magnetic resonance imaging, and 2-deoxy-2-[¹⁸F] fluoro-D-glucose PET scans identified a lesion in the thorax. ⁶⁸Ga-DOTA-TATE and ¹²³I-MIBG detected a total of 30 lesions, of which 29/30 were positive with ⁶⁸Ga-DOTA-TATE and 7/30 with ¹²³I-MIBG. We also found higher incidence of SDHB positive results in patients with positive ⁶⁸Ga-DOTA-TATE. Conclusion: Our limited data suggest that ⁶⁸Ga-DOTA-TATE is a better imaging agent for NCT and detects significantly more lesions with higher T/Nratio compared to ¹²³I- MIBG. ⁶⁸Ga-DOTA-TATE was more likely to detect malignant lesions as indicated by correlating imaging results with SDHB screening.
- ¹²³I-MIBG scintigraphy
- ⁶⁸Ga-DOTA-TATE PET
- Malignant neural crest tumours